109960.KQ Aprogen Healthcare & Games Inc
- Market cap
- KRW 26.6B
- P/E
- -
- P/B
- 0.07x
- ROE
- 23.8%
- Dividend yield
- -
- Fundamental score
- 1.4/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 109960.KQ undervalued?
Graham numberThe Graham number of Aprogen Healthcare & Games Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aprogen Healthcare & Games Inc fundamental analysis
7 of 22 checks passedROE 2/2
High return on equity (23.8%), above 20%.
ROA 1/1
Return on assets (22.6%) is above the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-259.9%) is below the industry median (28.7%).
Revenue Growth 1/2
Revenue grew 0.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
EBIT is 165.6x against interest expense, well covered.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.1x) is below the industry median (0.7x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Aprogen Healthcare & Games Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aprogen Healthcare & Games Inc
Aprogen Healthcare & Games Inc. engages in the development of medicines using biomedical technology. The company operates through Game Business, Rental Profit, and Pharmaceutical divisions. It offers specialty drugs, such as antibiotics, circulatory system, digestive system, anti-inflammatory, and analgesic drugs. The company also offers wireless remote lighting monitoring and control system for streetlights/security lamps, and Bluetooth hands-free for vehicles; rents bio eq…
Full company profileAprogen Healthcare & Games Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Aprogen Healthcare & Games Inc annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.82B | 11.2B | 17.6B | 21.9B | 10.3B | 8.42B | 9.60B | 16.0B | 16.4B | 9.81B | 11.7B |
| Gross Profit | -380M | 2.64B | 5.00B | 6.54B | 2.49B | 1.76B | 2.13B | 4.98B | 5.36B | 1.48B | 2.70B |
| Operating Income | -17.7B | -4.46B | -1.29B | -4.90B | -4.21B | -2.68B | -930M | -4.17B | 967M | 551M | 6.41B |
| EBITDA | - | - | - | - | - | - | 3.13B | 8.26B | -21.0B | -5.21B | 94.1B |
| Net Income | -22.7B | -3.30B | 8.74B | -6.75B | 11.1B | 2.65B | -5.61B | 4.30B | -28.1B | -5.56B | 85.9B |
| EPS | -528 | -33 | 49 | -38 | 62 | 74 | -157 | 38 | -140 | -504 | 5,679 |
| Balance Sheet | |||||||||||
| Total Assets | 15.6B | 142B | 238B | 218B | 237B | 227B | 213B | 317B | 335B | 320B | 379B |
| Total Liabilities | 6.97B | 26.9B | 20.5B | 7.87B | 5.06B | 4.13B | 14.5B | 29.3B | 33.1B | 13.9B | 17.8B |
| Shareholders' Equity | 8.64B | 115B | 217B | 210B | 232B | 223B | 199B | 287B | 302B | 307B | 362B |
| Cash & Short-term Investments | 5.78B | 70.4B | 47.0B | 46.0B | 31.7B | 56.4B | 91.3B | 10.2B | 42.7B | 4.13B | 4.09B |
| Total Debt | 381M | 16.8B | - | 1.19B | 445M | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.71B | 735M | 4.36B | 986M | 3.39B | -13.3B | 17.3B | 1.66B | 4.71B | 2.44B | 2.87B |
| Capital Expenditure | 303M | 10.9B | 42.1M | 96.3M | 30.0M | 5.72M | 0.00 | 25.0M | 81.9M | 14.1M | 24.7M |
| Free Cash Flow | - | - | - | - | 3.36B | -13.7B | 17.3B | 1.63B | 4.63B | 2.42B | 2.85B |
| Ratios | |||||||||||
| ROE | -263.2% | -2.9% | 4.0% | -3.2% | 4.8% | 1.2% | -2.8% | 1.5% | -9.3% | -1.8% | 23.8% |
| ROA | -145.7% | -2.3% | 3.7% | -3.1% | 4.7% | 1.2% | -2.6% | 1.4% | -8.4% | -1.7% | 22.6% |
| Net Profit Margin | -231.6% | -29.4% | 49.7% | -30.8% | 107.4% | 31.5% | -58.4% | 26.9% | -171.3% | -56.7% | 737.5% |
| Debt to Equity | 0.04x | 0.15x | - | 0.01x | 0.00x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aprogen Healthcare & Games Inc dividends
Aprogen Healthcare & Games Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Jun 1, 2026.
Who owns Aprogen Healthcare & Games Inc
- Insiders 59.70%
- Institutions 0.03%
- Public & others 40.27%
- Shares outstanding 179M
- Free float 71.9M
Aprogen Healthcare & Games Inc company profile
- Company name
- Aprogen Healthcare & Games Inc
- Ticker
- 109960.KQ
- ISIN
- KR7109960005
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Communications Equipment
- Employees
- 17
- Fiscal year end
- December
- Address
- Halla Sigma Valley B1, Seongnam-si, South Korea
- Phone
- 82 3 1782 3438
- Website
- aprogen-hng.com
About Aprogen Healthcare & Games Inc
Aprogen Healthcare & Games Inc. engages in the development of medicines using biomedical technology. The company operates through Game Business, Rental Profit, and Pharmaceutical divisions. It offers specialty drugs, such as antibiotics, circulatory system, digestive system, anti-inflammatory, and analgesic drugs. The company also offers wireless remote lighting monitoring and control system for streetlights/security lamps, and Bluetooth hands-free for vehicles; rents bio equipment; and leases real estate properties. In addition, it provides mobile games, such as Dragon Raja M, Legend of super heroes, Heroes & Titans, and Flame shadow. The company was formerly known as Locojoy International Corporation. Aprogen Healthcare & Games Inc. was founded in 1998 and is headquartered in Seongnam, South Korea.
Aprogen Healthcare & Games Inc management
5- Mr. Chang-Yong JungSr. Managing Director and Director of Light Control Division · born 1967
- Mr. Jang-Woon ParkChief of R&D Center and Managing Director · born 1967
- Mr. Yu-Chan KimManaging Director and Director of Management Support Division · born 1970
- Mr. Hui ChangChief Exec. Officer · born 1965
- Mr. Jung-Gwon LeeSr. Managing Director and Director of Wireless Solution Bus. Division · born 1967